Hypertension remains one of the most prevalent and modifiable risk factors for morbidity and mortality worldwide, particularly among older adults. With advancing age, both the prevalence and clinical consequences of elevated blood pressure increase substantially, contributing to a wide spectrum of cardiovascular and cerebrovascular diseases [1,2]. While the role of hypertension in cardiovascular outcomes is well established, growing evidence suggests that its impact on neurological health—especially stroke, cognitive decline, and dementia—is equally significant but often underrecognized in routine clinical practice.

Epidemiological studies have consistently demonstrated a strong, continuous, and age-dependent relationship between blood pressure levels and vascular mortality, including deaths attributable to stroke [2]. Even modest elevations in systolic blood pressure have been shown to markedly increase the risk of both ischemic and hemorrhagic stroke across all age groups, with the absolute risk being highest in older populations [1]. Meta-analyses of large prospective cohorts and randomized controlled trials confirm that blood pressure reduction significantly lowers the incidence of stroke and other major vascular events, reinforcing hypertension control as a cornerstone of preventive neurology [3].

Age-related changes in vascular structure and function, such as arterial stiffening and endothelial dysfunction, predispose older adults to isolated systolic hypertension, which is particularly harmful to cerebral circulation [5]. Untreated or inadequately controlled systolic hypertension in the elderly has been associated with increased risks of stroke, white matter lesions, cerebral microbleeds, and lacunar infarctions—pathologies closely linked to long-term neurological impairment [5,9]. Importantly, evidence suggests that appropriate antihypertensive treatment in older adults, including those aged 80 years and above, can significantly reduce the risk of stroke and all-cause mortality without unacceptable adverse effects [6].

Beyond overt cerebrovascular events, hypertension has profound implications for cognitive function and brain aging. Longitudinal studies have demonstrated that midlife and late-life hypertension are associated with accelerated cognitive decline and an increased risk of both vascular dementia and Alzheimer’s disease [8]. The relationship between blood pressure and cognition appears to be complex and age-dependent, with prolonged exposure to elevated blood pressure exerting cumulative damage on cerebral small vessels, leading to chronic hypoperfusion and neurodegeneration [8,15]. Recognizing hypertension as a determinant of cognitive health has shifted the focus of management from purely cardiovascular protection toward preservation of long-term brain health.

Interventional trials provide further support for this paradigm. Studies comparing intensive versus standard blood pressure control in older adults have shown that tighter blood pressure targets can reduce cardiovascular events and may also confer benefits in reducing the incidence of mild cognitive impairment [7,11]. However, concerns regarding cerebral hypoperfusion, falls, and adverse drug effects have led to ongoing debate about optimal blood pressure targets in the elderly, particularly in those with established cerebrovascular disease or frailty [17]. This underscores the need for population-specific evidence to guide balanced and individualized hypertension management strategies.

Stroke remains a leading cause of death and long-term disability globally, with older adults bearing a disproportionate burden [9,10]. Hypertension is implicated in both primary and secondary stroke prevention, influencing not only stroke occurrence but also stroke severity, recurrence, and post-stroke neurological outcomes [9,12]. Variability in blood pressure control, rather than absolute values alone, has also emerged as an important predictor of stroke risk and neurological deterioration, highlighting the importance of sustained and consistent hypertension management [13].

Despite robust international guidelines emphasizing early detection and effective treatment of hypertension [18], real-world control rates remain suboptimal, especially among older adults. Factors such as polypharmacy, comorbidities, poor adherence, and therapeutic inertia contribute to inadequate blood pressure control, potentially exacerbating neurological vulnerability in this age group [4,14]. Moreover, most existing studies focus on cardiovascular endpoints, with comparatively fewer investigations examining neurological outcomes as primary measures of interest in older hypertensive populations.

Given the increasing global burden of population aging and dementia, there is a pressing need to better understand how hypertension management influences neurological health outcomes in older adults. Evaluating the impact of blood pressure control on stroke incidence, cognitive function, and overall neurological well-being can inform integrated care models that align cardiovascular and neurological prevention strategies [15,16]. Such evidence is particularly relevant for developing settings, where the dual burden of uncontrolled hypertension and limited neurological care resources amplifies the public health impact.

Therefore, the present study aims to assess the impact of hypertension management on neurological health in older adults, focusing on key outcomes such as stroke, cognitive function, and neurological morbidity. By examining real-world patterns of blood pressure control and their neurological correlates, this study seeks to generate original evidence that can support optimized hypertension management strategies tailored to the aging population. Ultimately, improving hypertension control may represent a critical and achievable pathway toward preserving neurological health and functional independence in older adults.

Study Design and Setting This study was designed as an observational analytical study conducted among older adults diagnosed with hypertension. The study was carried out at a tertiary care teaching hospital over a defined study period of 12 months. The design was chosen to evaluate the real-world impact of hypertension management on neurological health outcomes, including stroke and cognitive function, in an elderly population receiving routine clinical care. Study Population The study population consisted of older adults aged 60 years and above with a documented diagnosis of hypertension for at least one year prior to enrollment. Participants were recruited from outpatient medicine clinics and inpatient wards using a consecutive sampling method. Inclusion Criteria • Age ≥60 years • Diagnosed hypertension (as per ACC/AHA criteria) for ≥1 year • On antihypertensive treatment (pharmacological and/or lifestyle modification) • Ability to provide informed consent • Willingness to undergo neurological and cognitive assessment Exclusion Criteria • History of major psychiatric illness • Known neurodegenerative disorders diagnosed prior to hypertension (e.g., Parkinson’s disease, Alzheimer’s disease) • Severe sensory impairment affecting cognitive testing • Terminal illness or severe systemic disease limiting participation • Acute stroke within the preceding 3 months Sample Size The sample size was calculated based on the expected prevalence of neurological complications among hypertensive older adults, using a confidence level of 95% and allowable error of 5%. After accounting for potential non-response, a minimum sample size of [insert calculated number] participants was targeted. Study Variables Exposure Variable Hypertension management status was the primary exposure variable and included: • Blood pressure control status (controlled vs uncontrolled) • Type of antihypertensive therapy (monotherapy vs combination therapy) • Intensity of blood pressure control (standard vs intensive targets) • Medication adherence (assessed by self-report and prescription review) Controlled hypertension was defined as an average systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg, based on recent guideline recommendations [18]. Outcome Variables Neurological health outcomes included: • History of stroke (ischemic or hemorrhagic, confirmed by medical records and imaging) • Cognitive function status • Presence of neurological deficits • Overall neurological morbidity Cognitive function was assessed using a standardized cognitive screening tool (e.g., Mini-Mental State Examination or Montreal Cognitive Assessment), with scores categorized into normal cognition, mild cognitive impairment, and cognitive impairment based on validated cut-offs. Covariates and Confounders Potential confounding variables recorded included: • Age, sex, and educational status • Duration of hypertension • Diabetes mellitus, dyslipidemia, smoking status • Body mass index (BMI) • History of cardiovascular disease • Blood pressure variability across visits Data Collection Procedure After obtaining informed consent, participants underwent structured interviews, clinical examination, and review of medical records. Blood pressure was measured using a calibrated sphygmomanometer following standard guidelines, with the average of two readings taken after five minutes of rest in a seated position. Neurological evaluation was performed by trained clinicians to assess motor, sensory, cranial nerve, and cerebellar function. Cognitive assessment was conducted in a quiet setting using validated tools in the participant’s preferred language. Details regarding antihypertensive medications, duration of therapy, adherence, and previous neurological events were documented using a pre-tested data collection proforma. Operational Definitions • Controlled hypertension: Mean BP <130/80 mmHg on at least two clinic visits • Uncontrolled hypertension: Mean BP ≥130/80 mmHg • Neurological morbidity: Presence of stroke, cognitive impairment, or persistent neurological deficits • Adequate hypertension management: Regular medication use with controlled blood pressure Statistical Analysis Data were entered into Microsoft Excel and analyzed using statistical software such as SPSS version 26. Continuous variables were expressed as mean ± standard deviation, while categorical variables were expressed as frequencies and percentages. Comparisons between controlled and uncontrolled hypertension groups were performed using: • Independent t-test or Mann–Whitney U test for continuous variables • Chi-square test or Fisher’s exact test for categorical variables Multivariable logistic regression analysis was used to assess the association between hypertension management and neurological outcomes after adjusting for confounders. Results were expressed as odds ratios (OR) with 95% confidence intervals. A p-value <0.05 was considered statistically significant. Ethical Considerations The study protocol was reviewed and approved by the Institutional Ethics Committee. Written informed consent was obtained from all participants prior to enrollment. Confidentiality of participant data was maintained throughout the study, and participation was entirely voluntary, with the option to withdraw at any time without affecting clinical care.

A total of 220 older adults with diagnosed hypertension were included in the final analysis after applying the inclusion and exclusion criteria. The mean age of the study population was 68.4 ± 6.3 years, with a range of 60 to 86 years. Of the participants, 118 (53.6%) were male and 102 (46.4%) were female. The majority of participants (61.8%) had been living with hypertension for more than five years.

Blood Pressure Control Status

Based on average blood pressure readings across two clinic visits, 124 participants (56.4%) had controlled hypertension, while 96 participants (43.6%) had uncontrolled hypertension. Participants with controlled hypertension were more likely to be on combination antihypertensive therapy and demonstrated higher medication adherence compared to those with uncontrolled blood pressure.

Baseline Clinical Characteristics

Comorbidities were common in the study population. Diabetes mellitus was present in 94 participants (42.7%), dyslipidemia in 88 participants (40.0%), and a prior history of cardiovascular disease in 46 participants (20.9%). These conditions were more prevalent among participants with uncontrolled hypertension, although the difference did not reach statistical significance for all comorbidities.

The mean systolic blood pressure in the controlled group was 124.6 ± 6.8 mmHg, compared to 148.2 ± 12.4 mmHg in the uncontrolled group. Diastolic blood pressure followed a similar pattern, with means of 76.3 ± 5.2 mmHg and 88.7 ± 7.9 mmHg, respectively.

Neurological Morbidity

Overall, 62 participants (28.2%) exhibited at least one form of neurological morbidity, including stroke, cognitive impairment, or persistent neurological deficits. Neurological morbidity was significantly higher among participants with uncontrolled hypertension (39.6%) compared to those with controlled hypertension (19.4%, p < 0.001).

Stroke Outcomes

A total of 38 participants (17.3%) had a documented history of stroke. Ischemic stroke accounted for 31 cases (81.6%), while 7 cases (18.4%) were hemorrhagic. Stroke prevalence was significantly higher in the uncontrolled hypertension group (25.0%) compared to the controlled group (11.3%, p = 0.006).

Participants with uncontrolled hypertension also demonstrated a higher frequency of recurrent stroke and greater residual neurological deficits, including hemiparesis and speech impairment.

Cognitive Function Assessment

Cognitive assessment revealed that 74 participants (33.6%) had some degree of cognitive impairment. Of these, 52 participants (23.6%) met criteria for mild cognitive impairment, while 22 participants (10.0%) demonstrated moderate to severe cognitive impairment.

Cognitive impairment was more prevalent in the uncontrolled hypertension group (45.8%) than in the controlled group (24.2%, p = 0.002). Mean cognitive scores were significantly lower among participants with uncontrolled blood pressure control, even after adjusting for age and educational status.

Blood Pressure Control and Cognitive Scores

A significant inverse correlation was observed between systolic blood pressure levels and cognitive scores (r = −0.36, p < 0.001). Participants with longer duration of uncontrolled hypertension showed progressively lower cognitive performance, suggesting a dose–response relationship between blood pressure exposure and cognitive decline.

Blood pressure variability across clinic visits was also associated with poorer cognitive outcomes. Participants in the highest quartile of systolic blood pressure variability had significantly lower cognitive scores compared to those with stable blood pressure control.

Multivariable Analysis

Multivariable logistic regression analysis was performed to identify independent predictors of neurological morbidity. After adjusting for age, sex, diabetes, dyslipidemia, smoking status, and duration of hypertension, uncontrolled hypertension remained a significant independent predictor of neurological morbidity (adjusted OR: 2.31; 95% CI: 1.34–3.98; p = 0.002).

Similarly, uncontrolled hypertension was independently associated with increased odds of stroke (adjusted OR: 2.08; 95% CI: 1.12–3.87) and cognitive impairment (adjusted OR: 1.89; 95% CI: 1.10–3.25).

Medication Adherence and Neurological Outcomes

Participants reporting high medication adherence demonstrated significantly lower rates of neurological morbidity (18.7%) compared to those with poor adherence (41.9%, p < 0.001). High adherence was associated with better blood pressure control and improved cognitive scores, highlighting the role of consistent hypertension management in neurological protection.

Table 1. Socio-demographic and Clinical Characteristics of Study Participants (n = 220)

Table 2. Blood Pressure Control Status and Treatment Characteristics (n = 220)

Table 3. Neurological Morbidity According to Blood Pressure Control Status (n = 220)

Table 4. Cognitive Function Status and Blood Pressure Control (n = 220)

The present study demonstrates a clear and clinically meaningful association between hypertension management and neurological health outcomes in older adults. Participants with adequately controlled blood pressure exhibited significantly lower rates of stroke, cognitive impairment, and overall neurological morbidity compared to those with uncontrolled hypertension. These findings reinforce the growing recognition that hypertension is not only a cardiovascular risk factor but also a major determinant of long-term neurological health in the aging population [1,2]. Our observation that uncontrolled hypertension was associated with more than a two-fold increase in neurological morbidity is consistent with prior epidemiological and interventional studies linking elevated blood pressure to cerebrovascular damage and brain injury [1,3]. Large-scale meta-analyses have shown that sustained blood pressure reduction substantially lowers the risk of stroke across age groups, with older adults deriving the greatest absolute benefit due to higher baseline risk [3]. The current study extends these findings by demonstrating that the neurological consequences of poor blood pressure control extend beyond acute stroke events to include chronic cognitive impairment. Stroke prevalence in this cohort was significantly higher among participants with uncontrolled hypertension, with ischemic stroke accounting for the majority of cases. This aligns with established evidence that hypertension contributes to atherosclerosis, small vessel disease, and embolic phenomena, which are central mechanisms in ischemic stroke pathogenesis [9,12]. Furthermore, the higher burden of residual neurological deficits observed in the uncontrolled group underscores the role of blood pressure management not only in stroke prevention but also in mitigating post-stroke disability. Cognitive impairment was a prominent finding in this study, affecting over one-third of participants, with a significantly higher prevalence among those with uncontrolled hypertension. This supports prior longitudinal studies that have identified hypertension as a key risk factor for accelerated cognitive decline and dementia, particularly through its effects on cerebral small vessels and white matter integrity [8,15]. The observed inverse correlation between systolic blood pressure and cognitive scores suggests a dose–response relationship, whereby prolonged exposure to elevated blood pressure may lead to cumulative brain injury and neurodegeneration. The association between blood pressure variability and poorer cognitive outcomes observed in this study further highlights the importance of consistent blood pressure control. Visit-to-visit variability has been shown to independently predict stroke and cognitive decline, potentially through repeated episodes of cerebral hypoperfusion and endothelial stress [13]. This finding emphasizes that optimal hypertension management should focus not only on achieving target blood pressure levels but also on minimizing fluctuations over time. Our findings are also consistent with evidence from randomized trials comparing intensive and standard blood pressure control strategies. Studies such as SPRINT have demonstrated that intensive blood pressure lowering in older adults reduces cardiovascular events and may lower the incidence of mild cognitive impairment [7,11]. However, concerns regarding adverse effects in frail elderly individuals persist. The present study, conducted in a real-world clinical setting, suggests that achieving guideline-recommended blood pressure targets is associated with neurological benefits without apparent excess harm, supporting the feasibility of effective hypertension control in older adults [18]. Medication adherence emerged as a key modifiable factor influencing neurological outcomes in this study. Participants with high adherence rates had significantly lower neurological morbidity, underscoring the central role of sustained antihypertensive therapy in protecting brain health. Poor adherence has been widely recognized as a major barrier to effective hypertension control, particularly in older populations with polypharmacy and comorbidities [4,14]. Addressing adherence through patient education, simplified regimens, and regular follow-up may therefore yield substantial neurological benefits. The findings of this study align with contemporary frameworks emphasizing optimal brain health as a lifelong goal. The American Heart Association has highlighted hypertension control as a foundational strategy for preserving cognitive function and reducing the burden of dementia at the population level [15,16]. In this context, hypertension management represents a low-cost, high-impact intervention with the potential to significantly reduce neurological disability in aging societies. Despite its strengths, including comprehensive neurological assessment and adjustment for major confounders, this study has certain limitations. The observational design limits causal inference, and cognitive assessment relied on screening tools rather than detailed neuropsychological testing. Additionally, neuroimaging markers of cerebral small vessel disease were not systematically evaluated. Future longitudinal studies incorporating imaging biomarkers and longer follow-up are needed to further elucidate the causal pathways linking hypertension management to neurological outcomes. In conclusion, this study provides original evidence that effective hypertension management is strongly associated with better neurological health in older adults. Controlled blood pressure was linked to lower risks of stroke, cognitive impairment, and overall neurological morbidity. These findings support the integration of neurological outcomes into hypertension management strategies and reinforce the importance of sustained blood pressure control as a key determinant of healthy brain aging. Strengthening hypertension care in older adults may therefore play a critical role in reducing the growing burden of neurological disease worldwide [9,10,18].

1. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35(3):776–785.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913.
3. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
4. Franklin SS, Wong ND. Hypertension and cardiovascular disease: contributions of the Framingham Heart Study. Glob Heart. 2013;8(1):49–57.
5. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355(9207):865–872.
6. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898.
7. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 75 years or older. JAMA. 2016;315(24):2673–2682.
8. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487–499.
9. Diener HC, Hankey GJ. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage. J Am Coll Cardiol. 2020;75(15):1804–1818.
10. Ovbiagele B, Goldstein LB, Higashida RT, Howard VJ, Johnston SC, Khavjou OA, et al. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke. 2013;44(8):2361–2375.
11. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116.
12. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2018;49(3):e46–e110.
13. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895–905.
14. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370(9587):591–603.
15. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, et al. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016;68(6):e67–e94.
16. Gorelick PB, Furie KL, Iadecola C, Smith EE, Waddy SP, Lloyd-Jones DM, et al. Defining optimal brain health in adults. Stroke. 2017;48(10):e284–e303.
17. Bath PM, Appleton JP, Krishnan K, Sprigg N. Blood pressure in acute stroke: to treat or not to treat. Stroke. 2018;49(7):1784–1790.
18. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13–e115.